GLA 與頑症、危疾

在已發展國家,癌症是導致死亡的第二大元兇。一般抗癌藥物非選擇性地殺死癌細胞與正常細胞,其副作用亦影響了很多患者的生活質量。

飲食輔助(如補充多元不飽和脂肪酸)已被證明可以透過改善細胞膜流動性而增強藥物療效並減低副作用。GLA 被認為是其中一種可輔助化療的多不飽和脂肪酸,包括乳腺異變細胞,胰腺異變細胞,結腸異變細胞,腦異變細胞等。
2,3,6,9
tumor_angiogenesis

GLA 與頑症

在前臨床研究中,GLA 已被證明可發揮以下的抗異變細胞活性:

  • 抑制異變細胞轉移7
  • 抑制異變細胞中血管增生7
  • 刺激異變細胞細胞凋亡 / 死亡7
  • 選擇性地殺死異變細胞1

GLA 和其他化療藥物之間的協同作用

GLA 本身不僅可直接殺死異變細胞,也可以與多種化療藥物產生協同作用,如 paclitaxel5, vinorelbine8, doxorubicin4, mitoxantrone 和 idarubicin10, 5-fluorouracil和 germcitabine6 更值得注意的是,一針對乳腺異變細胞的臨床試驗中證實了合併服用 GLA 與藥物 tamoxifen 能提高藥物的療效,減少的副作用及縮短治療反應時間3,這進一步表明 GLA 可與化療藥物一同應用並作為輔助療法。


參考文獻

    • Undurti N. From bench to the clinic: γ-linolenic acid therapy of human gliomas. Prostaglandins, leukotrienes and essential fatty acids. 2004: 70, 539-552.
    • Mainou-Fowler T et al. Gamma-linolenic acid induces apoptosis in B-chronic lymphocytic leukaemia cells in vitro. Leuk Lymphoma. 2001 Jan;40(3-4):393-403.
    • Frances S. KENNY et al. Int. J. Cancer. 2000: 85, 643–648.
    • J.A. Plumb et al. Effect of polyunsaturated fatty acids on the drug sensitivity of human tumor cell lines resistant to either cisplatin or doxorubicin. Br. J. Cancer 1993; 67, 728-733.
    • J.A. Menendez et al. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. European Journal of Cancer. 2001: 37, 402-413.
    • P.A. Whitehouse et al. Pancreatology. 2003: 3, 367-374.
    • J. Cai et al. Inhibition of angiogenic factor- and tumor-induced angiogenesis by gamma linolenic acid. Prostaglandins, leukotrienes and essential fatty acids.1999: 60, 21-29.
    • Javier Abel Menendez et al. 2002: 72, 203-219.
    • WG Jiang et al. Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. British Journal of Cancer. 1995: 71, 744-752.
    • C.L. Davies et al. Effect of γ-linolenic acid on cellular uptake of structurally related anthracyclines in human drug sensitive and multidrug resistant bladder and breast cancer cell lines. European Journal of Cancer. 1999: 35, 1534-1540.